MedTrace Logo

Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs

NCT06641596 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2024-10-15

No results posted yet for this study

Summary

A randomized, double-blind, placebo controlled, parallel study to determine if Chromium (Cr), Phyllanthus emblica (PE) and Shilajit (SJ) supplementation and Phyllanthus emblica fruit extract supplementation promotes greater changes in glucose homeostasis, endothelial function, and cardiometabolic risk in sedentary and overweight men and women initiating an exercise and weight loss program.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

2 capsules of Placebo, once daily after breakfast for 12 weeks

DIETARY_SUPPLEMENT

Cr-400

1 capsule of Cr-400 + 1 capsule of Placebo, once a day after breakfast for 12 weeks

DIETARY_SUPPLEMENT

Cr-800

2 capsules of Cr-400, once a day after breakfast for 12 weeks

DIETARY_SUPPLEMENT

PE-500

1 capsule of PE + 1 capsule of Placebo, once a day after breakfast for 12 weeks

DIETARY_SUPPLEMENT

PE-1000

2 capsules of PE-500, once a day after breakfast for 12 weeks

Sponsors & Collaborators

  • Kerry Group P.L.C

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2024-01-30
Completion
2024-05-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06641596 on ClinicalTrials.gov